VRL/SEC/NSE/92

May 22, 2012

National Stock Exchange of India Ltd.,
5th Floor , Exchange Plaza
Bandra (E), Mumbai- 400 051

Sub. : Venus Remedies bags another patent grant from South Africa

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has received its first patent for a novel antibiotic combination of carbapenem and aminoglycoside. Pioneering into antibacterial portfolio, Venus has added another international patent from CIPRO (Companies and Intellectual Property Registration Office) South Africa to its basket for the antibiotic combination rationally designed to result in a pharmaceutical low dose. Overall, Venus is enjoying a total tally of more than 80 patents for its innovative research products across the globe.

Venus Medicine Research Centre (VMRC) is constantly working on innovating new technologies and drugs for eradicating the most fatal diseases in the world. The Company has made amazing progress to treat serious fatal mixed multi-bacterial infectious diseases through our novel antibiotic combination of Carbapenem and Aminoglycoside. Having received this patent grant from CIPRO, South Africa, Venus is hopeful of capturing a major share in the market which is upheaval with antibiotics for wide indications. With probable prolonged administration of most of the existing therapies, this proposed single unit injection will be a blessing for the medical fraternity as it is extremely effective even at very low concentrations. This will significantly overcome the drug resistance problem and will also reduce the side effects.

Novel antibiotic combination is suitable for the treatment of bacterial/ multi-bacterial infections, and is particularly suitable for catering to the needs of all age groups ranging from the neonates, children, immuno compromised patients, and the ones prone to serious fatal mixed multi-bacterial infectious diseases.

In case of neonates and children, where higher doses may precipitate serious toxicities and lower doses of existing therapies do not work, dose reduction to a therapeutically effective level with reduced side effects was the greatest accomplishment with the novel antibiotic combination.

The global anti-infectives market generated revenues of $79.12bn from second quarter 2008 to second quarter 2009. Over this period, the systemic antibacterial market accounted for 46.9% of this market segment reaching $37.14bn in revenues. Overall growth for the forecast period from 2009 to 2024 is estimated to be 6.76% (CAGR) rising to a figure of $99.13bn.

Product is under development in accordance to the stringent international guidelines defined for developing a new drug. Efficacy and Safety studies established through a series of microbiological studies carried out as per CLSI guidelines. Venus expects the product to be in market by end of 2015 after regulatory approvals.

Yours faithfully,
for VENUS REMEDIES LIMITED.

Ramanjit

Ramanjit Kaur
Assistant Manager
Corporate Communication

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 22 May 2012 15:37 P 1